- Home
- IRON vs MTX Comparison
IRON vs MTX Comparison
Compare IRON & MTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- MTX
- Stock Information
- Founded
- IRON 2017
- MTX 1968
- Country
- IRON United States
- MTX United States
- Employees
- IRON N/A
- MTX N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- MTX Major Chemicals
- Sector
- IRON Health Care
- MTX Industrials
- Exchange
- IRON Nasdaq
- MTX Nasdaq
- Market Cap
- IRON 2.0B
- MTX 1.7B
- IPO Year
- IRON N/A
- MTX 1992
- Fundamental
- Price
- IRON $59.82
- MTX $63.62
- Analyst Decision
- IRON Strong Buy
- MTX Strong Buy
- Analyst Count
- IRON 10
- MTX 2
- Target Price
- IRON $97.80
- MTX $82.00
- AVG Volume (30 Days)
- IRON 301.7K
- MTX 217.2K
- Earning Date
- IRON 11-11-2025
- MTX 10-23-2025
- Dividend Yield
- IRON N/A
- MTX 0.68%
- EPS Growth
- IRON N/A
- MTX N/A
- EPS
- IRON N/A
- MTX 0.06
- Revenue
- IRON N/A
- MTX $2,063,500,000.00
- Revenue This Year
- IRON N/A
- MTX N/A
- Revenue Next Year
- IRON N/A
- MTX $4.53
- P/E Ratio
- IRON N/A
- MTX $955.48
- Revenue Growth
- IRON N/A
- MTX N/A
- 52 Week Low
- IRON $30.82
- MTX $49.54
- 52 Week High
- IRON $68.73
- MTX $86.49
- Technical
- Relative Strength Index (RSI)
- IRON 50.30
- MTX 54.29
- Support Level
- IRON $58.59
- MTX $61.68
- Resistance Level
- IRON $61.27
- MTX $65.19
- Average True Range (ATR)
- IRON 2.13
- MTX 1.53
- MACD
- IRON -0.15
- MTX -0.20
- Stochastic Oscillator
- IRON 18.47
- MTX 42.72
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About MTX Minerals Technologies Inc.
Minerals Technologies Inc mines, produces, and sells mineral-based products. The firm organizes itself into two segments: The Consumer & Specialties segment that derives maximum revenue, serves consumer end markets directly with mineral-to-market finished products and also provides specialty mineral-based solutions and technologies that are an essential component of our customers' finished products. The Engineered Solutions segment serves industrial end markets with engineered systems, mineral blends, and technologies that are designed to improve our customers' manufacturing processes and projects. The majority of revenue comes from the United States.